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Abstract
The Centers for Disease Control and Prevention and the American Congress of Obstetricians and 
Gynecologists recommend universal prenatal HIV testing to prevent perinatal HIV transmission in 
the U.S.; since the 1990s perinatal HIV transmission has declined. In 2006, 74% of women with a 
recent live birth reported testing for HIV prenatally or at delivery. We used Pregnancy Risk 
Assessment Monitoring System data from 36 states and New York City from 2004 to 2013 (N = 
387,424) to assess characteristics associated with lack of self-reported testing and state-to-state 
variability in these associations. Overall, 75.2% (95% confidence interval [CI] 75.0–75.5) of 
women with a recent live birth reported an HIV test. There were significant differences in testing 
prevalence by state, ranging from 91.8% (95% CI 91.0–92.6) in New York to 42.3% (95% CI 
41.7–43.5) in Utah. In adjusted analysis, characteristics associated with no reported testing 
included being married, white, non-Hispanic, multiparous, not smoking during pregnancy, and 
having neither Medicaid nor Special Supplemental Nutritional Program for Women, Infants, and 
Children. White married women were 57% (adjusted prevalence ratio [aPR] 1.57, 95% CI 1.52–
1.63) more likely to report no test compared to white unmarried women. Multiparous married 
women were 57% (aPR 1.57, 95% CI 1.51–1.64) more likely to report no test compared to 
multiparous unmarried women. Women who were married, white, non-Hispanic, and multiparous 
women were 23% less likely to be tested than other women combined. Marital status was 
significantly associated with lower prevalence of testing in 35 of the 37 reporting areas, and race 
was significant in 30 of 35 states with race information. The prevalence of reported HIV testing 
during pregnancy or at delivery remains below 80%. Opportunities exist to increase HIV testing 
among pregnant women, particularly among certain subpopulations.
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Introduction
Although HIV transmission in the U.S. remains a public health concern, HIV transmission 
from mothers to infants during pregnancy, delivery, or postpartum is now rare.1,2 Since the 
late 1990s, perinatal HIV acquisition has been reduced 96%, to 1.75/100,000 in 2013.2 
Through advances in pharmaceutical and clinical research, guidelines development, and 
changes to clinical practice, the number of HIV-infected children born in the U.S. decreased 
from an estimate of 1650 in 1991 to 69 in 2013, and perinatal transmission rates decreased 
from 35% to less than 3%.1,2
Five steps in clinical care contribute to reduce perinatal transmission; the first is the 
diagnosis of maternal HIV infection, which evolved from a counseling and testing approach 
to an ‘opt-out’ approach at prenatal care intake, or at delivery for those with undocumented 
HIV testing during pregnancy.3,4 The second involves provision of antiretroviral therapy for 
all HIV-infected pregnant women through pregnancy, delivery, and postpartum; third is 
consideration of cesarean delivery; fourth is alternatives to maternal breastfeeding;5 fifth is 
infant antiretroviral prophylaxis.6
The Centers for Disease Control and Prevention (CDC) and the American Congress of 
Obstetricians and Gynecologists (ACOG) now recommend universal HIV testing early 
during pregnancy, a second test in the third trimester for women at high risk, and testing at 
labor and delivery for those with undocumented HIV status.3–5 Testing is critical to 
prevention since it allows for consideration and implementation of the five steps above;6 
these five can reduce the risk of mother-to-child transmission to less than 1%.7 However, 
although state laws and national guidelines and recommendations support universal HIV 
testing during each pregnancy,3–5 and testing is cost effective even at very low prevalence,8 
not all women receive a test.9,10
A companion paper11 using the Pregnancy Risk Assessment Monitoring System (PRAMS) 
examined trends in self-reported HIV testing rates from 2004 to 2011 (the most current 
available) in relation to state policies and found little to no change in the testing rate over 
time. We used PRAMS data from 2004 to 2013 to assess whether characteristics differed 
between tested women and not tested women, nationally and by state, in order to inform 
policy-makers and clinicians about opportunities to increase communication and testing.
Methods
PRAMS is an ongoing population-based surveillance collaboration between CDC and state 
health departments that identifies and monitors selected maternal experiences, behaviors, 
and conditions before, during, and after pregnancy.12 During each annual surveillance period 
during 2004–2013, PRAMS surveyed a sample of postpartum women who delivered a live-
Koumans et al. Page 2
Int J STD AIDS. Author manuscript; available in PMC 2019 August 19.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
born infant; in 2013, the survey was being administered in 36 participating states and New 
York City. Our sample represents approximately 70% of all live births in the United States 
during this period13,14 (Appendix A in online supplemental files).
A state’s birth certificate file serves as the sampling frame; each state uses the same 
standardized mailtelephone methodology. Between two and four months following delivery, 
surveys are sent by mail to the birth mother; mail nonrespondents are contacted via 
telephone. PRAMS-participating state health departments select and employ state-specific 
stratification schemes, oversampling subpopulations of particular public health interest, such 
as mothers of low birthweight infants and racial/ethnic minority groups. Annual sample 
sizes vary by state (see Appendix A in online supplemental files), with larger sample sizes 
for larger states or those with more complex stratification schemes.14,15 In each state, self-
reported survey data are linked to birth certificate data for each year and weighted for 
sample design, nonresponse, and nonco-verage to be representative of all women who gave 
birth to a live-born infant. Detailed information about the PRAMS methodology is available 
(http://www.cdc.gov/prams/methodology.htm). The CDC and local Institutional Review 
Boards approved the PRAMS protocol and use of deidentified data by investigators for 
secondary analyses.
PRAMS requires that published data meet or exceed minimum weighted response rates of 
70% for years 2004–2006, 65% for years 2007–2011, and 60% for 2012 and 2013. We used 
PRAMS data from 36 states and New York City (hereafter referred to as ‘states’) meeting 
these criteria, combining the years 2004–2013, representing 70% of live births (see 
Appendix A and Appendix B in online supplemental files). All participating PRAMS sites 
approved this analysis.
Variables
Pregnancy-related characteristics explored were based on previous literature.9,10 Data on 
maternal demographic characteristics (maternal age, education, race, ethnicity, and marital 
status) were derived from the birth certificate, while pregnancy intention; parity; income; 
enrollment in the Special Supplemental Nutritional Program for Women, Infants, and 
Children (WIC) and Medicaid; smoking status during last trimester; alcohol use (before and 
during pregnancy); length of delivery hospital stay; physical abuse; hospitalization during 
pregnancy; and prenatal care visits (onset, number) were based on self-report from the 
PRAMS questionnaire. Since income data are collected by states for local purposes, the 
income categories used by states do not always match; we used the following categories and 
fit states’ data as appropriate into the closest fitting category: $0-$15,000, $15,000-$50,000, 
or greater than $50,000.
Since questions assessing insurance coverage during pregnancy and delivery changed during 
2004–2013, women who answered ‘yes’ to the question about whether they had Medicaid 
(2004–2008), answered ‘Medicaid’ to the question about the type of insurance for prenatal 
care and delivery (2009–2011), or answered ‘Medicaid’ to the question about the type of 
insurance during prenatal care (2012–2013) were classified as having Medicaid. Because 
WIC and Medicaid status were collinear, we combined responses for insurance and WIC 
into the following categories: neither Medicaid nor WIC, WIC only, Medicaid only, or both. 
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We used the Kessner index (measure of timing and number of visits) as an indicator of 
prenatal care quality,16 classified maternal education based on years of school completed, 
and pregnancy intention using the following question, ‘Thinking back to just before you got 
pregnant with your new baby, how did you feel about becoming pregnant?’ Women who 
answered that they wanted their pregnancy ‘sooner’ or ‘then’ were classified as having an 
intended pregnancy, and those who answered ‘later,’ ‘did not want,’ or ‘did not want at any 
time’ were classified as having an unintended pregnancy.
Outcome
Women were asked if they had received a test for HIV during prenatal care visits or at 
delivery. For this analysis, we used this question ‘At any time during your most recent 
pregnancy or delivery, did you have a test for HIV (the virus that causes AIDS)?’ 
Respondents who answered ‘yes’ or ‘no’ were included in the analysis.
Analysis
Sample weights were used in all analyses to account for unequal probability of selection. 
SAS-callable SUDAAN (RTI International, Research Triangle Park, NC) was used to 
account for the stratified complex survey design; we present weighted estimates. We used 
Chi square tests to examine differences in distribution of characteristics between women 
tested and not tested for HIV. We performed multivariable analyses with main effects in 
bivariate analyses with P < 0.15. Nonsignificant effects were removed stepwise from the 
model; this was repeated until a parsimonious model with all significant effects at P < 0.001 
was observed. Because the national sample was very large, the overall final multivariable 
logistic regression model included main effects, then main effects variables were examined 
for two-way interactions; terms of p< 0.001 were retained. Because more than 10% of 
women reported no HIV test during pregnancy or at delivery, for the national analysis we 
calculated adjusted prevalence ratios (aPRs) by using predicted marginals from logistic 
regression models and then converting these estimates to prevalence ratios.17
Results
A total of 37 PRAMS states reported one or more years of data during 2004–2013, for a 
total unweighted sample size of 387,424. Appendix A and Appendix B in the online 
supplemental files include yearly state-specific sample sizes and response rates.
On reporting of an HIV test, 334,166 (86%) responded ‘yes’ or ‘no’ and were included. 
Among included women, 53.4% (for 95% confidence interval [CI] see Table 1) were aged 
25–34 years, 70.9% were white, 16.9% were Hispanic, 60.9% were married, 29.2% made 
less than $15,000 per year, 42.0% had delivered their first child, 58.8% had intended 
pregnancies, 11.5% smoked in their last trimester, 36.8% received both Medicaid and WIC, 
66.8% reported adequate prenatal care (Table 1). In addition, 89.2% (95% CI 89.1–89.4) 
were hospitalized for four days or less for delivery, 55.6% (95% CI 55.4–56.0) had more 
than 12 years of education, 52.2% (95% CI 52.0–52.5) drank alcohol three months before 
pregnancy, 7.0% (95% CI 6.9–7.2) drank in the last three months of pregnancy, and 4.5% 
(95% CI 4.3–4.6) were physically abused before pregnancy.
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Overall, 75.2% (95% CI 75.0–75.5) of women with a recent live birth reported receiving an 
HIV test during pregnancy or at delivery. The prevalence of HIV testing varied by state and 
ranged from 42.6% (95% CI 41.7–43.5) in Utah to 91.8% (95% CI 91.0–92.6) in New York 
(NY); an analysis of annual state HIV testing rates is provided elsewhere.11 Nationally, the 
prevalence of HIV testing by year ranged from 71.9% (95% CI 71.2–72.7) in 2013 to 77.5% 
(95% CI 76.878.1) in 2005. Compared to unmarried women (85.3%; 95% CI 85.1–85.7), 
fewer married women reported testing (68.8%; 95% CI 68.5–69.1); compared to black 
women (90.0%; 95% CI 89.6–90.4) or women of other race (77.4%; 95% CI 76.8–78.0), 
fewer white women (72.5%; 95% CI 71.2–71.8) reported testing. Other characteristics 
associated with lower reported rates of HIV testing in bivariate analysis include Hispanic 
ethnicity, Medicaid or WIC coverage, age, education, parity, income, intendedness of 
pregnancy, smoking in the last trimester, and prenatal care quantity and timing (Kessner 
index16) (Table 1).
When examining differences by state, NY had the highest testing rate (91.8%). Subgroup 
HIV testing differences were smaller in NY than in the other states. In NY, 94.5% (95% CI 
93.2–95.7) of women with Medicaid and WIC, 92.1% (95% CI 88.9–95.2) of women with 
Medicaid only, 92.1% (95% CI 89.5–94.7) of women with WIC only, 90.0% (88.9–91.2) of 
women with neither Medicaid nor WIC, 94.5% (95% CI 93.3–95.6) of unmarried women, 
90.0% (95% CI 89.0–91.1) of married women, 94.0% (95% CI 91.6–96.4) of black women, 
91.3% (95% CI 90.4–92.2) of white women, 92.3% (95% CI 90.2–94.4) of women of other 
races, and 94.7% (95% CI 92.9–96.4) of Hispanic women were tested for HIV prenatally or 
during delivery.
In multivariable analyses, marital status, race, ethnicity, Medicaid/WIC status, parity, and 
smoking in the last trimester remained significantly associated with HIV testing; four 
interactions (marital status with race, marital status with ethnicity, and marital status with 
parity; and Medicaid/WIC status with parity) remained significant (Table 2). Married white 
women were 57% (aPR = 1.57, 95% CI 1.52–1.63) more likely, married black women were 
27% (aPR = 1.27, 95% 1.17–1.38) more likely, and married women of other races were 25% 
(aPR = 1.25; 95% CI 1.17–1.33) more likely to report not getting a test compared their 
same-race, unmarried counterparts. Married Hispanic women were 32% (aPR = 1.32; 95% 
CI 1.24–1.42) more likely and married non-Hispanic women were 52% (aPR = 1.52; 95% 
CI 1.48–1.57) more likely to report no testing compared to their same-ethnicity, unmarried 
counterparts. Combined, women who were unmarried, non-white, Hispanic, or primiparous 
reported testing at 87.5% (95% CI 86.9–88.1), while 61.9% (95% CI 61.4–62.4) of women 
who were married, white, or multiparous reported testing. Women who were married, white, 
non-Hispanic, and multiparous (27% of the PRAMS sample) were 23% more likely to report 
not getting an HIV test than all other women combined.
In state-specific multivariable analyses, the following characteristics remained significantly 
associated with HIV testing during pregnancy or at delivery in the following number of 
states; marital status: 35 of 37 states (95%); race: 30 of 35 states (86%); Medicaid/WIC 
receipt: 31 of 37 states (84%); smoking: 23 of 37 states (62%); ethnicity: 21 of 37 states 
(57%); parity: 24 of 37 states (65%) (Table 3).
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Discussion
Among women with a recent live birth who participated in PRAMS during 2004–2013, the 
overall rate of HIV testing during pregnancy or at delivery was 75%, which is similar to the 
rate found in 2006,9 similar to two smaller analyses using claims data from 2007 (62%) and 
2008 (74.1%) that also examined syphilis testing,18,19 and similar annually to the year-by-
year analysis of 2004–2011 PRAMS data in a companion article.11 There has been no 
appreciable change since ACOG released universal testing recommendations in 2004, which 
were updated in 2008 and in 2015,4 or since 2004–2006, when CDC revised 
recommendations on HIV testing to state that all pregnant women should be tested as early 
as possible during each pregnancy.3,5
We found differences in testing rates during pregnancy or delivery among certain 
subpopulations of women. Married, multiparous, white, non-Hispanic women were less 
likely to report testing than their counterparts; we found significant interactions between 
several of these variables, which may not have been elucidated in studies with smaller 
sample sizes. The characteristics associated with self-report of nonreceipt of an HIV test 
included marital status, race, Hispanic ethnicity, Medicaid/WIC status, parity, and smoking 
in the last trimester of pregnancy. In comparison, in 2005–2006, medical records from 4762 
pregnant women were reviewed for documentation of HIV testing; 74% had evidence of 
testing before delivery. Women who did not have documentation of testing were more likely 
to be non-Hispanic, white, and use non-Medicaid insur-ance,9 similar to our findings. 
Characteristics we identified as significant on bivariate analysis are consistent with another 
study.10 An analysis of 2002 NSFG data found an overall reported testing rate during 
prenatal care of 69%; women less likely to report an HIV test were those reporting higher 
(versus lower) income and those with some college education (versus not completing high 
school).10 The study’s small sample size of 768 women, however, may have limited the 
ability to assess multiple characteristics and interactions. Education and income, while 
significant in univariate analysis, dropped from our multivariate model.
Compared to all other women in the sample, women who were married, white, non-
Hispanic, and multiparous were 23% less likely to report testing. Providers may consider 
married, white, and non-Medicaid or WIC-receiving women to be at low risk for HIV. 
However, the emergence of local HIV transmission, including to pregnant women, 
associated with parenteral opioid drug use in a predominantly rural, white county in Indiana 
indicates that undetected transmission may be occurring among women considered ‘low 
risk.’20 The reasons for the lower testing rate among married, white, non-Hispanic, and 
multiparous women are unclear but may involve differences in individual or health care 
systems approaches to prenatal care: biases by providers or care systems, and policies 
differentially applied or implemented. Research to describe factors leading to no testing 
among different groups of women, even those who reported higher rates, may provide 
insight into potential interventions to improve testing rates.
The Healthy People 2020 target for HIV prenatal testing is 79.5%.21 Our analysis indicates 
that testing rates are near this target (75.3%). CDC estimated that there were still more than 
8000 women of reproductive age who were diagnosed with HIV infection in 2014.2 Because 
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U.S. women and their infants continue to become infected with HIV, efforts are needed to 
increase testing, especially in the populations we identified as having low testing coverage. 
HIV testing is cost effective (savings are greater than costs) at a rate of 7.5/100,000 or one 
out of 13,333 pregnant women.8 Previous publications suggest the ‘opt-out’ approach, in 
which all women are tested unless they specifically opt out of testing, could maximize 
routine screening to provide universal HIV testing. This approach limits the need for lengthy 
counseling and may improve testing rates despite lingering stigma.5,22 Fitz Harris et al. 
analyzed PRAMS data by year (2004–2012) and assessed the effect of state policies or laws 
in the last ten years to improve testing. They found that areas where testing rates have 
increased implemented policy changes, passed laws, or worked with providers on quality 
initiatives that may have led to increased testing.11 Areas where HIV testing has remained 
stable or decreased may benefit from implementing successful activities.
Because PRAMS data are self-reported and women may be screened as part of routine 
prenatal care on an opt-out basis, some women may not know that they have been tested for 
HIV, particularly if health care providers do not discuss negative test results. Therefore, this 
analysis may underestimate actual testing. PRAMS does not ask about repeat testing during 
pregnancy (or about infant testing), so we could not assess adherence to the repeat testing 
recommendation. The sensitivity and specificity of the PRAMS HIV testing question was 
examined by comparing PRAMS data to medical records in New York City and Vermont in 
2009.23 The authors found that the sensitivity (women who reported testing to PRAMS, of 
all women tested) was 89.6 and 67.7%, the specificity (women reporting no testing to 
PRAMS, of all women not tested) 14.7 and 61.6%, and the positive predictive value 98.3 
and 90.8% in NYC and Vermont, respectively. We only analyzed the ‘yes’ responses to 
indicate testing and did not analyze the ‘no’ responses. Based on the published sensitivity, 
we likely underestimate the true prevalence of HIV testing during pregnancy or at delivery. 
If a correction from NY and VT were applied to other states, the testing rate reported here 
would be estimated at between 84 and 100%. However, testing rates using claims data found 
similar results to this analysis.18,19
Other limitations include the respondents’ missing income data (n = 36,146), that not all 
states reported race, and that we did not assess subgroup trends by state. However, 
consistently significant differences among characteristics of women reporting HIV testing 
across states suggest that testing is not uniform. Women may decline testing if they recall 
that they have been tested in the recent past.24 Current recommendations state that women at 
high risk for HIV should be tested twice during pregnancy.4,5 PRAMS does not distinguish 
between prenatal or delivery testing, nor assess whether high-risk women are getting a 
second test in the third trimester, as is currently recommended.
These data represent 36 states and one city; notably, because of low response rates, several 
southern states participating in PRAMS did not contribute data or did not contribute each 
year (see Appendix A in online supplemental files). While 2002 data from NSFG found 
higher testing rates in southern states,10 year-to-year variations in state-specific testing rates 
from 2004 to 2011 are available and southern states had lower testing rates in more recent 
years.11 Inclusion of data from these states might have lowered the estimate. Despite these 
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limitations, our data suggest that improvements in HIV testing coverage are possible, 
particularly among subpopulations often considered low risk and certain states.
In summary, in this PRAMS analysis, we found that during 2004–2013, one out of every 
four women with a recent live birth reported not being tested for HIV during pregnancy or at 
delivery. The testing rate has not changed substantially in the last ten years.11 HIV testing is 
cost effective and universal testing is recommended by ACOG and CDC; local efforts to 
implement universal HIV testing may reduce differences in testing rates between 
subpopulations and further reduce perinatal transmission.
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